Senator Rick Scott (R-FL) asks
@RushDoshi, director of
@CFR_China, about what the potential consequences for the United States could be if China restricts just 25% of the inputs for amoxicillin. “The ability to have a shortage or an increase in price, I mean, that will ripple though the health-care system,” says Doshi.
“At least 700 [U.S. drugs] have an upstream dependency on [key starting materials (KSMs)] that come from only China. So we’re talking about, potentially, a magnitude of impact that would be devastating to seniors.”